Collision tumor of the thyroid – a challenge during the COVID-19 pandemic

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Dec 18, 2021
DOI: https://doi.org/10.22551/2021.33.0804.10189
Mihaela Vlad Ana Corlan Melania Balas Ioana Golu Daniela Amzar Emil Bistrian Marioara Cornianu

Abstract

Some of the patients with anaplastic thyroid carcinomas have a coexistent differentiated thyroid cancer, sustaining the hypothesis that this cancer may develop from more differentiated tumors. We describe a case with a collision tumor of the thyroid, defined as a neoplastic lesion composed of two distinct cell populations, with distinct borders. The patient presented during the COVID-19 pandemic with dysphonia, dyspnea, multinodular goiter and a painless, rapidly enlarging, left cervical swelling. She had been first time diagnosed with left nodular goiter in 2007, with an indication for surgery, which she declined. After partial excision of the left latero-cervical adenopathy, the pathological analysis showed massive lymph node metastasis from anaplastic thyroid cancer. A total thyroidectomy was done; the postoperative pathological exam identified a papillary thyroid microcarcinoma in the right lobe and an anaplastic thyroid cancer in the left lobe. Postoperatively, levothyroxine treatment was started and the patient was referred to radiotherapy. This case highlights the importance of urgent management of some cases with compressive multinodular goiter, even during the COVID-19 pandemic.

##plugins.themes.bootstrap3.article.details##

Keywords

collision tumor, anaplastic thyroid cancer, papillary thyroid microcarcinoma, dedifferentiation

References
1. Ragazzi M, Ciarrocchi A, Sancisi V, Bisagni A, Piana S. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014; 790834. https://doi.org/10.1155/2014/790834
2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006; 13(4):453-464. https://doi.org/10.1245/ASO.2006.05.042
3. Scosyrev E, Messing J, Noyes K, Veazie P, Messing E. Surveillance epidemiology and end results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012; 30(2):126-132. https://doi.org/10.1016/j.urolonc.2009.11.005
4. Yau T, Lo CY, Epstein RJ, Lam AKY, Wan KY, Lang BH. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol. 2008; 15(9):2500-2505. https://doi.org/10.1245/s10434-008-0005-0
5. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001; 130(6):1028-1034. https://doi.org/10.1067/msy.2001.118266
6. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7):1330-1305. https://doi.org/10.1002/cncr.20936
7. Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995; 17(1):41-47. https://doi.org/10.1002/hed.2880170109
8. Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. 1985; 60(1):51-58. https://doi.org/10.1016/s0025-6196(12)65285-9
9. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985; 83(2):135-158. https://doi.org/10.1093/ajcp/83.2.135
10. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine - refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69(11):4885-4893. https://doi.org/10.1158/0008-5472.CAN-09-0727
11. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017; 14(5):587-595. https://doi.org/10.1016/j.jacr.2017.01.046
12. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006; 13(2):119-128. https://doi.org/10.1177/107327480601300206
13. Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996; 40(5):953-958. https://doi.org/10.1159/000334007
14. Takano K, Kikuchi K, Matsumiya H, Himi T. Collision tumor of the thyroid: follicular carcinoma plus papillary carcinoma plus adenomatous goiter. World J Med Surg Case Rep. 2013; 2:21-25.
15. Molnar C, Molnar S, Bedekovics J, et al. Thryoid carcinoma coexisting with Hashimotos thyroiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res. 2019; 25(3):1191-1197. https://doi.org/10.1007/s12253-019-00580-w
16. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992; 18(2):83-88.
17. Saunders CA, Nayar R. Anaplastic spindle-cell squamous carcinoma arising in association with tall-cell papillary cancer of the thyroid: a potential pitfall. Diagn Cytopathol. 1999; 21:413-418. https://doi.org/10.1002/(sici)1097-0339(199912)21:6<413::aid-dc10>3.0.co;2-n
18. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126:1052-1066. https://doi.org/10.1172/JCI85271
19. Rushton S, Burghel G, Wallace A, Nonaka D. Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma. Histopathology. 2016; 69:524-526. https://doi.org/10.1111/his.12964
20. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E – mutant anaplastic thyroid cancer. J Clin Oncol. 2018; 36:7-13. https://doi.org/10.1200/JCO.2017.73.6785
21. Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E - mutated anaplastic thyroid carcinoma. Thyroid. 2019; 29(8):1036-1043. https://doi.org/10.1089/thy.2019.0133
22. Bible KC, Kebebew E, Brierley J, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021; 31(3):337-386. https://doi.org/10.1089/thy.2020.0944
23. Anand A, Singh KR, Kushwaha JK, Hussain N, Sonkar AA. Papillary thyroid cancer and Hashimotos thyroiditis: an association less understood. Indian J Surg Oncol. 2014; 5(3):199-204. https://doi.org/10.1007/s13193-014-0325-4
24. Lun Y, Wu X, Xia Q, et al. Hashimotos thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013; 148(3):396-402. https://doi.org/10.1177/0194599812472426
How to Cite
Vlad, M., Corlan, A., Balas, M., Golu, I., Amzar, D., Bistrian, E., & Cornianu, M. (2021). Collision tumor of the thyroid – a challenge during the COVID-19 pandemic. Archive of Clinical Cases, 8(4), Arch Clin Cases 2021; 8(4):64-71. https://doi.org/10.22551/2021.33.0804.10189
Issue
Vol. 8 No. 4 (2021): Thyroid Cancer
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Vlad, M., Corlan, A., Balas, M., Golu, I., Amzar, D., Bistrian, E., & Cornianu, M. (2021). Collision tumor of the thyroid – a challenge during the COVID-19 pandemic. Archive of Clinical Cases, 8(4), Arch Clin Cases 2021; 8(4):64-71. https://doi.org/10.22551/2021.33.0804.10189